Loading clinical trials...
Loading clinical trials...
Prospective Observational Study to Evaluate Persistence With Prolia® (Denosumab) in Postmenopausal Women With Osteoporosis in Routine Clinical Practice
The objective of this study was to describe persistence with Prolia® 60 mg administered subcutaneously (SC) every 6 months (Q6M) at 12 and 24 months.
The study was a multi-center, single-arm, prospective, non-interventional observational study in postmenopausal women with osteoporosis who had been treated with Prolia® for osteoporosis in routine clinical practice.
Age
All ages
Sex
FEMALE
Healthy Volunteers
No
Research Site
Birmingham, Alabama, United States
Research Site
Chandler, Arizona, United States
Research Site
Peoria, Arizona, United States
Research Site
Phoenix, Arizona, United States
Research Site
Hemet, California, United States
Research Site
Laguna Hills, California, United States
Research Site
Los Angeles, California, United States
Research Site
Murrieta, California, United States
Research Site
Oxnard, California, United States
Research Site
Santa Maria, California, United States
Start Date
July 6, 2011
Primary Completion Date
April 7, 2014
Completion Date
April 14, 2014
Last Updated
November 29, 2022
935
ACTUAL participants
Lead Sponsor
Amgen
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions